Indivior /£INDV
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Indivior
Indivior PLC, listed under the ticker symbol INDV, is a global pharmaceutical company. Founded in 2014, it primarily focuses on developing medications for the treatment of addiction and serious mental illnesses. The company operates in the pharmaceuticals sector, providing innovative treatment solutions globally.
Ticker
£INDV
Sector
Primary listing
LSE
Industry
Pharmaceuticals
Headquarters
Employees
1,041
ISIN
GB00BN4HT335
Website
Indivior Metrics
BasicAdvanced
£1.5B
-
-£0.36
0.34
-
Price and volume
Market cap
£1.5B
Beta
0.34
52-week high
£11.79
52-week low
£5.55
Average daily volume
227K
Financial strength
Current ratio
0.879
Quick ratio
0.642
Long term debt to equity
-119.649
Total debt to equity
-129.825
Interest coverage (TTM)
8.38%
Profitability
EBITDA (TTM)
230.217
Gross margin (TTM)
81.62%
Net profit margin (TTM)
-5.30%
Operating margin (TTM)
24.36%
Effective tax rate (TTM)
-8.77%
Revenue per employee (TTM)
£834,440
Management effectiveness
Return on assets (TTM)
12.60%
Return on equity (TTM)
45.09%
Valuation
Price to revenue (TTM)
1.739
Price to book
-5.16
Price to tangible book (TTM)
-5.03
Price to free cash flow (TTM)
19.947
Free cash flow yield (TTM)
5.01%
Free cash flow per share (TTM)
58.75%
Growth
Revenue change (TTM)
4.09%
Earnings per share change (TTM)
-1,489.27%
3-year revenue growth (CAGR)
12.67%
10-year revenue growth (CAGR)
0.76%
3-year earnings per share growth (CAGR)
-24.72%
10-year earnings per share growth (CAGR)
-15.26%
What the Analysts think about Indivior
Analyst ratings (Buy, Hold, Sell) for Indivior stock.
Bulls say / Bears say
Indivior's plan to shift its primary listing from London to New York aims to attract more U.S. investors and potentially increase its inclusion in major U.S. stock indices, reflecting its strong U.S. market presence where 85% of sales are generated. (ft.com)
The company reported robust financial performance for 2023, with $1.1 billion in sales and $223 million in adjusted net income, driven significantly by its opioid addiction treatment, Sublocade. (ft.com)
Indivior's inclusion in the U.S. Russell 2000® and 3000® Indexes as of June 30, 2025, may enhance its visibility and attract a broader investor base. (indivior.com)
Indivior issued its second profit and revenue warnings in three months due to lower than expected sales from its opioid addiction treatment, Sublocade, impacted by rapid adoption of the competing drug Brixadi. (reuters.com)
The company faced a significant 40% drop in share price and a strategic shift towards streamlining product offerings and R&D activities due to legal issues and competitive pressures. (ft.com)
Indivior lowered its profit forecast for 2024, indicating a decline in sales of its primary opioid addiction treatment, Sublocade, and decided to discontinue sales of its schizophrenia drug, Perseris, resulting in 130 job cuts. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Indivior Financial Performance
Revenues and expenses
Indivior Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Indivior stock?
Indivior (INDV) has a market cap of £1.5B as of July 18, 2025.
What is the P/E ratio for Indivior stock?
The price to earnings (P/E) ratio for Indivior (INDV) stock is 0 as of July 18, 2025.
Does Indivior stock pay dividends?
No, Indivior (INDV) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Indivior dividend payment date?
Indivior (INDV) stock does not pay dividends to its shareholders.
What is the beta indicator for Indivior ?
Indivior (INDV) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.